证券代码：002099 证券简称：海翔药业 公告编号：2023-047 浙江海翔药业股份有限公司 关于为合并报表范围内子公司提供担保的进展公告 2023 年 2 月 3 日，公司与汇丰银行（中国）有限公司签署《保证书》，同 意为香港港翔开展各类银行业务提供 1,650 万元美金连带责任担保，具体详见 公司于 2023 年 2 月 4 日在《证券时报》、《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）上披露的《关于为合并报表范围内子公司提供担保的进 展公告》（公告编号：2023-005）。 二、担保进展情况 2023 年 8 月 28 日，公司与汇丰银行（中国）有限公司重新签署新《保证 书》，同意公司继续为香港港翔开展各类银行业务提供 1,650 万元美金连带责 任担保。原《保证书》于新《保证书》签署之日起失效。本次对外担保系原担 保到期后展期，未新增担保额度。 三、保证书的主要内容 1、担保金额：1,650 万元美金。 2、担保方式：连带责任担保。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江海翔药业股份有限公司（以 ...

浙江海翔药业股份有限公司 股票代码：002099 股票简称：海翔药业 公告编号：2023-046 欢迎广大投资者积极参与。 特此公告。 浙江海翔药业股份有限公司 董 事 会 二零二三年八月三十日 关于举行 2023 年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2023 年 8 月 30 日披露 了 2023 年半年度报告。为了让广大投资者能进一步了解公司 2023 年半年度的经 营情况，公司将于 2023 年 9 月 6 日下午 15:00 至 17:00 在深圳证券交易所互动 易平台举办 2023 年半年度业绩说明会，与投资者进行沟通交流，听取投资者的 意见和建议。本次业绩说明会将采用网络远程方式举行，投资者可登录深圳证券 交易所互动易平台（http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次 业绩说明会。 公司出席本次业绩说明会的人员有：公司总经理许国睿、董事会秘书兼财务 总监王晓洋、独立董事俞永平。（如有特殊情况，参与人员会有调整） 为充分尊重投资者 ...

证券代码：002099 证券简称：海翔药业 公告编号：2023-043 浙江海翔药业股份有限公司 第七届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届监事会第三次会议 于 2023 年 8 月 18 日以电子邮件形式发出通知，于 2023 年 8 月 28 日以现场方 式在公司会议室召开，会议应出席监事 3 人，实际出席监事 3 人，公司部分董 事、高级管理人员列席会议。会议召开符合《公司法》及《公司章程》的规定， 合法有效。会议由监事会主席陈敏杰先生主持，经过与会监事的充分讨论，会议 审议通过了如下议案： 一、审议通过了《2023 年半年度报告及摘要》 监事会认为董事会编制和审核公司《2023 年半年度报告》的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《2023 年半年度报告全文》及《2023 年半年度报告摘要》（公告编号： 2023-044）于 2023 年 8 月 30 日刊登在巨 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届董事会第五次会 议于 2023 年 8 月 18 日以电子邮件形式发出通知，于 2023 年 8 月 28 日以现场 加视频方式在公司会议室召开，会议应出席董事 8 人，实际出席董事 8 人，其 中，王扬超先生、姚冰先生、陶红女士、王晓洋女士出席现场会议，许国睿先 生、俞永平先生、钱建民先生、梁超女士以视频方式参会，公司监事、高级管 理人员列席会议。会议召开符合《公司法》及《公司章程》的规定，合法有 效。会议由董事长王扬超先生主持，经过与会董事的充分讨论，会议审议通过 了如下议案： 一、审议通过了《2023 年半年度报告及摘要》 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 《2023 年半年度报告全文》及《2023 年半年度报告摘要》（公告编号： 2023-044）于 2023 年 8 月 30 日刊登在巨潮资讯网，《2023 年半年度报告摘 要》同时刊登于《证券时报》、《证券日报》、《上海证券报》。 二、审议通过了《2023 年半年度募集资金存放 ...

3、截至 2023 年 6 月 30 日，公司除对合并报表范围内子公司担保外，不存 在为控股股东及其他关联方提供担保的情况，未有逾期对外担保。公司对外担 保均符合（证监会公告〔2022〕26 号）以及《公司章程》的规定，履行了必要 的审议和决策程序，信息披露充分完整。 （本页无正文，为《浙江海翔药业股份有限公司独立董事关于第七届董事会第 五次会议相关事项的独立意见》之签字页） 浙江海翔药业股份有限公司 独立董事关于第七届董事会第五次会议相关事项的独立意见 根据中国证监会《上市公司独立董事管理办法》、《深圳证券交易所股票 上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》和《公司章程》等有关规定，作为公司独立董事，在审阅有关文 件及尽职调查后，基于独立判断的立场，对公司第七届董事会第五次会议相关 事项发表意见如下： 一、关于公司关联方资金占用和对外担保情况的专项说明和独立意见 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管 要求》（证监会公告〔2022〕26 号）等相关规定的要求，作为公司的独立董 事，基于独立判断立场，为了维护公司及股东特别是中小股东的 ...

根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求》和深圳证券交易所印发的《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》的规定，将本公司募 集资金 2023 年半年度存放与使用情况专项说明如下。 一、募集资金基本情况 证券代码：002099 证券简称：海翔药业 公告编号：2023-045 浙江海翔药业股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2016〕765 号文核准，并经深圳证券 交易所同意，本公司由主承销商国泰君安证券股份有限公司采用非公开发行方 式，向特定对象非公开发行人民币普通股(A 股)股票 99,890,023 股，发行价为 每股人民币 10.28 元，共计募集资金 1,026,869,436.44 元，坐扣承销费和保荐 费等 10,000,000.00 元(含税)后的募集资金为 1,016,869,436.44 元，已由主承 销商国 ...

Financial Performance - The company reported a total revenue of 1.5 billion RMB for the last fiscal year, representing a year-over-year growth of 15%[29]. - The company achieved a total operating revenue of CNY 2.704 billion in 2022, representing an increase of 8.83% compared to 2021[32]. - The company has provided a revenue guidance of 1.8 billion RMB for the next fiscal year, indicating a projected growth of 20%[29]. - The company achieved a net profit of 300 million RMB, reflecting a net profit margin of 20%[29]. - The net profit attributable to shareholders was CNY 88.01 million, a decrease of 7.58% from the previous year[32]. - The company reported a non-operating income of ¥24,626,661.74 in 2022, an increase of 47.1% compared to ¥16,745,362.17 in 2021[130]. - Total revenue for 2022 reached ¥2,704,144,046.05, representing an 8.83% increase from ¥2,484,828,437.08 in 2021[182]. Dividend and Profit Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of 0.5 RMB per 10 shares (including tax) based on a total of 1,618,715,253 shares[3]. - The company did not propose a cash dividend distribution plan despite positive profits available for distribution to shareholders[191]. - The cash dividend policy is compliant with the company's articles of association and shareholder resolutions, ensuring transparency and clarity in the dividend standards and ratios[198]. Research and Development - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[29]. - The company is actively developing new products and has submitted applications for consistency evaluations for several generic drugs[43]. - The R&D investment as a percentage of operating income was 5.36%, down from 6.63% in the previous year[59]. - The company has multiple ongoing R&D projects aimed at expanding its product pipeline, including cardiovascular and diabetes-related raw materials[58]. - The company has a strong focus on R&D for high-barrier specialty raw materials, with several projects in the validation or trial production stages[165]. - The company has established a national-level enterprise technology center and has completed 13 national projects and 35 provincial projects, holding 64 domestic invention patents and 4 PCT patents[171]. Market and Customer Base - The user base has expanded to 5 million active users, an increase of 25% compared to the previous year[29]. - Market expansion efforts include entering two new international markets, projected to increase overall market share by 10%[29]. - The company has a strong international customer base, maintaining long-term collaborations with major pharmaceutical companies such as Pfizer and Novartis, and its specialty raw materials are exported to multiple countries[173]. - The company’s sales revenue for the penem series increased by 60% year-on-year, with market share gradually rising[165]. - Domestic revenue reached approximately CNY 1.22 billion, accounting for 45.18% of total revenue, reflecting a 9.66% increase compared to the previous period[169]. - International revenue was approximately CNY 1.48 billion, representing 54.82% of total revenue, with an 8.15% growth compared to the previous period[169]. Compliance and Governance - The company emphasizes its commitment to ensuring the accuracy and completeness of its financial reports, with all board members present for the meeting[3]. - The company operates under the regulatory guidelines of the Shenzhen Stock Exchange for the chemical industry, ensuring compliance with disclosure requirements[3]. - The company's board of directors operates in compliance with legal and regulatory requirements, ensuring fair treatment of all shareholders[129]. - The company is committed to strict compliance with safety, environmental, and quality regulations to avoid potential risks[123]. Financial Health and Cash Flow - The cash flow from operating activities was CNY 116.09 million, up 13.41% from 2021[32]. - Total cash inflow from operating activities increased by 28.73% to ¥2,512,818,932.03 in 2022 from ¥1,951,965,146.22 in 2021[70]. - Net cash flow from operating activities rose by 13.41% to ¥116,092,038.77 in 2022 compared to ¥102,360,758.31 in 2021[70]. - The net increase in cash and cash equivalents was -¥550,973,287.70, a 56.80% decline compared to -¥351,394,028.30 in 2021[70]. - The proportion of cash and cash equivalents to total assets decreased from 22.79% at the beginning of 2022 to 17.76% at the end of 2022, a reduction of 5.03%[80]. Strategic Initiatives - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 500 million RMB allocated for potential deals[29]. - The company aims to optimize its human resource management system to improve operational management levels and enhance employee motivation[122]. - The company is focused on cost reduction and efficiency improvement to enhance profitability and sustainable development[122]. - The company has established a biochemistry platform for enzyme discovery and fermentation, integrating discovery, development, and commercial production capabilities[179]. Production and Capacity - The company has a current API production capacity of over 1,200 tons, with an additional 970 tons under construction, and an intermediate production capacity of over 2,800 tons, with 3,200 tons also under construction[103]. - The company has completed the installation of equipment for its sterile powder injection production line, with a designed capacity of 50 million units[103]. - The company has expanded its CDMO project management efficiency, engaging in over 30 CDMO customer projects and entering commercial order phases for several projects expected to grow significantly in 2023[179]. - The company has developed a flexible production platform and completed 30 projects in small and pilot tests during the reporting period, focusing on new product development and CMO/CDMO project advancement[181]. Environmental and Social Responsibility - The company has made significant investments in environmental protection facilities, including a solid waste incineration capacity of 45,000 tons per year, enhancing its waste treatment capabilities[176]. - The company has received multiple environmental impact assessment approvals for various projects, indicating ongoing expansion and compliance with regulations[170].

Financial Performance - The company's operating revenue for the current period is ¥634,047,833.60, a decrease of 21.19% compared to the same period last year[20]. - Total operating revenue for the current period is $634.05 million, down 21.14% from $804.53 million in the previous period[33]. - Net profit attributable to shareholders for the current period is ¥42,101,946.61, down 51.62% year-over-year[20]. - Net profit for the current period is $41.85 million, a decrease of 51.66% compared to $86.55 million in the previous period[34]. - Basic and diluted earnings per share are both ¥0.02, down 60.00% from ¥0.05 in the previous year[20]. - The net profit after deducting non-recurring gains and losses is -¥3,289,938.74, representing a decline of 104.29% compared to the previous year[20]. Cash Flow - Net cash flow from operating activities was CNY 159,451,304.75, a slight increase from CNY 149,627,750.29, reflecting a growth of approximately 5.5%[14]. - Cash flow from financing activities generated a net inflow of CNY 603,707,509.29, compared to a net outflow of CNY -4,572,083.35 in the previous period[15]. - The company reported a net cash inflow from investing activities of CNY 81,685,962.84, a significant recovery from a net outflow of CNY -118,848,272.85 in the previous period[14]. - Net cash flow from investing activities improved by 168.73% to 81,685,962.84 from -118,848,272.85 mainly due to the recovery of investments and dividends[46]. - Net cash flow from financing activities increased significantly by 13,304.21% to 603,707,509.29 from -4,572,083.35 due to increased bank borrowings[46]. Assets and Liabilities - Total liabilities increased to CNY 2,912,033,729.61, up from CNY 2,288,184,973.02, representing a growth of approximately 27.2% year-over-year[10]. - The company’s total assets reached CNY 9,058,797,473.33, up from CNY 8,393,099,770.24, representing an increase of approximately 7.9%[10]. - Current assets totaled 4,027,776,667.20, up from 3,245,690,461.75, indicating a significant increase in liquidity[50]. - Cash and cash equivalents increased to 2,305,531,103.61 from 1,490,815,956.57, reflecting improved cash management[50]. - Total assets rose to 9,058,797,473.33 from 8,393,099,770.24, indicating growth in the company's asset base[50]. - Non-current assets decreased to 5,031,020,806.13 from 5,147,409,308.49, showing a reduction in long-term investments[50]. Shareholder Information - The company reported a total of 32,095 common shareholders at the end of the reporting period[27]. - The largest shareholder, Zhejiang Donggang Industrial Co., Ltd., holds 32.37% of the shares, totaling 523,982,587 shares[27]. - Shareholders' equity attributable to the parent company is ¥6,150,080,587.84, a slight increase of 0.24% compared to the previous year[20]. Operating Costs and Expenses - Total operating costs decreased to $642.13 million, a reduction of 9.25% from $708.00 million in the previous period[33]. - Financial expenses increased significantly to $24.96 million, up 547.97% from $3.85 million in the previous period, primarily due to exchange losses from the depreciation of the US dollar[44]. - Operating expenses increased by 96.56% to 245,032.99 from 124,663.16 primarily due to an increase in fixed asset scrapping[46]. - Income tax expenses decreased by 84.46% to 2,221,604.16 from 14,293,732.25 due to a reduction in total profit[46]. Foreign Exchange and Other Income - The company experienced significant foreign exchange losses due to large fluctuations in exchange rates during the reporting period[41]. - Non-operating income includes government subsidies of ¥3,564,265.41 and gains from the disposal of non-current assets of ¥8,248,695.14[21]. - Investment income rose to $20.09 million, an increase of 244.93% from $5.82 million in the previous period, mainly due to received dividends[44]. - The company reported a significant increase in asset disposal gains to $8.30 million, up 5023.79% from $162,040.17 in the previous period[44].

股票代码：002099 股票简称：海翔药业 公告编号：2023-021 浙江海翔药业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 特此公告。 浙江海翔药业股份有限公司 董 事 会 二零二三年四月二十五日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日披露 了2022年年度报告。为了让广大投资者能进一步了解公司2022年度的经营情况， 公司将于 2023 年 5 月 5 日下午 15:00 至 17:00 在深圳证券交易所互动易平台举 办 2022 年度业绩说明会，与投资者进行沟通交流，听取投资者的意见和建议。 本次业绩说明会将采用网络远程方式举行，投资者可登录深圳证券交易所互动易 平台（http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次业绩说明会。 公司出席本次业绩说明会的人员有：公司董事长王扬超、总经理许国睿、董 事会秘书王晓洋、财务总监朱勇、独立董事梁超。（如有特殊情况，参与人员会 有调整） 为充分尊重投资者、提升交流的针对性，现就公司 ...